Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 16Recurrence 3Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Triple Negative Breast Neoplasms 1Proteostasis Deficiencies 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hematologic Neoplasms 1Chromosome 17 deletion 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Burkitt Lymphoma 1Breast Neoplasms 1Amyloidosis 1Alzheimer Disease 1

Interventions

pembrolizumab 26Nivolumab 10Cisplatin 9Gemcitabine 8Docetaxel 6enfortumab vedotin 5atezolizumab 5Ipilimumab 5Carboplatin 5sacituzumab govitecan 4Paclitaxel 4Pemetrexed 3Cyclophosphamide 3vofatamab 2tremelimumab 2tislelizumab 2regorafenib 2lenvatinib 2epacadostat 2durvalumab 2avelumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Biopsy 2Bevacizumab 2B701 protein, Human herpesvirus 6 2ALT-803 2yeast-CEA vaccine 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Transitional Cell × ixazomib × Clear all
NCT02420847 2025-11-10

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
57 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡